Merrimack Pharmaceuticals Inc, announced detailed results from NAPOLI-1,
a large, randomised, three-arm Phase 3 study of MM-398, a nanoliposomal
encapsulation of irinotecan, in patients with metastatic pancreatic
cancer previously treated with gemcitabine-based therapy. The
combination of MM-398 with 5-fluorouracil (5-FU) and leucovorin extended
overall survival and significantly increased progression free survival
(PFS) and overall response rate compared to the control arm of 5-FU and
leucovorin alone.
Top line results of NAPOLI-1 released in May showed that the combination of MM-398 with 5-FU and leucovorin achieved an overall survival of 6.1 months versus the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. The primary log-rank analysis of overall survival was statistically significant (p=0.012), with a corresponding hazard ratio of 0.67.
Top line results of NAPOLI-1 released in May showed that the combination of MM-398 with 5-FU and leucovorin achieved an overall survival of 6.1 months versus the 4.2 month survival demonstrated by the control arm of 5-FU and leucovorin alone. The primary log-rank analysis of overall survival was statistically significant (p=0.012), with a corresponding hazard ratio of 0.67.
No comments:
Post a Comment